Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany
- 345 Downloads
To document the development of resistance to tigecycline in comparison with 17 other antimicrobials, the susceptibilities of 2,741 isolates comprising 16 bacterial species recovered from hospitalised patients in 15 German centres in 2009 were assessed. The results were compared with those of previous trials (German Tigecycline Evaluation Surveillance Trial, G-TEST I and II, performed in 2005 and 2007, respectively) conducted prior to and shortly after the introduction of tigecycline in Germany. Moreover, the in vitro activities of tigecycline against the subset of multidrug-resistant (MDR) pathogens recovered within all three sampling periods (n = 4,988) were evaluated in comparison to the corresponding non-MDR isolates. All susceptibility tests were performed by broth microdilution. Between 2005 and 2009, tigecycline retained its high activity against Gram-positive and Gram-negative organisms, including MDR pathogens. By contrast, an in part marked increase in resistance to broad-spectrum beta-lactams and fluoroquinolones was observed for many Enterobacteriaceae and for non-fermenting Gram-negative bacteria. Against a background of a steadily increasing number of multiresistant pathogens, the activity of tigecycline remained unaltered. With the exception of Acinetobacter isolates with decreased susceptibility to carbapenems, tigecycline’s activity profile was not notably affected by organisms resistant to other drug classes and, thus, holds promise as an important therapeutic agent, particularly for situations in which MDR organisms are suspected.
The study was supported by Pfizer Pharma GmbH, Berlin.
Conflict of interest
MK, KB and HS have received travel, research grant support and/or lecture fees from Pfizer. EL, CvE and P-AL are employees of Pfizer Pharma GmbH.
- 4.Bundesministerium für Gesundheit, Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz, und Bundesministerium für Bildung und Forschung (2008) DART—Deutsche Antibiotika-ResistenzstrategieGoogle Scholar
- 11.European Antimicrobial Resistance Surveillance System (EARSS) (2009) EARSS Annual Report 2008Google Scholar
- 20.Kresken M, Leitner E, Seifert H, Peters G, von Eiff C (2009) Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis 28:1007–1011PubMedCrossRefGoogle Scholar
- 21.Deutsches Institut für Normung (DIN) (2006) Labormedizinische Untersuchungen und In-vitro-Diagnostika-Systeme—Empfindlichkeitsprüfung von Infektionserregern und Evaluation von Geräten zur antimikrobiellen Empfindlichkeitsprüfung, Teil 1: Referenzmethode zur Testung der In-vitro-Aktivität von antimikrobiellen Substanzen gegen schnell wachsende aerobe Bakterien, die Infektionskrankheiten verursachen (ISO 20776–1:2006). Beuth-Verlag, BerlinGoogle Scholar
- 22.European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2010) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1 April 2010Google Scholar
- 23.Clinical and Laboratory Standards Institute (CLSI) (2009) Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S19. CLSI, Wayne, PAGoogle Scholar
- 24.Clinical and Laboratory Standards Institute (CLSI) (2008) Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement (M100-S18). CLSI, Wayne, PAGoogle Scholar
- 30.Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821–825PubMedCrossRefGoogle Scholar
- 31.Bonilla H, Huband MD, Seidel J, Schmidt H, Lescoe M, McCurdy SP, Lemmon MM, Brennan LA, Tait-Kamradt A, Puzniak L, Quinn JP (2010) Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 51:796–800PubMedCrossRefGoogle Scholar
- 32.Lautenbach E, Fishman NO, Metlay JP, Mao X, Bilker WB, Tolomeo P, Nachamkin I (2006) Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis 194:79–85PubMedCrossRefGoogle Scholar
- 33.Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, Kuyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ (2003) Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis 37:1643–1648PubMedCrossRefGoogle Scholar